Willow Announces Partnership with a Leading Pharma Firm To Develop Sustainable Intermediates

The Nasdaq-listed biopharma company and Willow Biosciences Inc. will work together to create new sustainable manufacturing routes for essential intermediates and active pharmaceutical ingredients (APIs). Willow Biosciences Inc. is a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, reliable, and sustainable functional ingredients. In order to produce intermediates and APIs with less expense and waste, Willow's collaborative partner saw the need to use more sustainable manufacturing techniques. They turned to Willow for help creating and scaling critical ingredients.

The initial initiative will concentrate on determining whether creating a biobased approach is feasible and, if successful, advance development toward commercial deployment. This financed collaboration's development phase is anticipated to take about two months. The name of the partner and other details are withheld at this time due to the competitive nature of the targeted ingredient uses. "We are honored to have been selected by such a forward-thinking biopharmaceutical company to jointly explore innovative pathways toward the development of sustainably sourced intermediates and APIs," said Dr. Chris Savile, Willow's President & CEO. "If successful, we believe that by leveraging biobased routes, these ingredients essential for human health can be made more broadly available while providing a solution for overseas supply chain issues that can increase cost and potentially create shortages." This arrangement is the fifth new development agreement that Willow has signed in 2023, and a strong pipeline of additional possible partnerships is now under consideration.